Navigation Links
FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
Date:6/27/2008

nt in everyday functioning," said Janet Vergis, President of McNeil Pediatrics(TM). "Recognizing this need -- and as the market leader in extended-release MPH for children and adolescents -- we see today's approval as a treatment option milestone for adults with ADHD and their healthcare professionals. We are proud to offer patients ages 6 to 65 with ADHD our CONCERTA(R) product knowledge based on more than seven years of clinical experience."

Researchers examining ADHD across the lifespan have noted the condition is often chronic, with prominent symptoms and impairment spanning into adulthood, and is often associated with co-occurring anxiety, mood and disruptive disorders as well as substance abuse(3). According to the NIMH, ADHD is thought to be a biological condition, usually inherited, and tends to run in some families more than others. Often when a child is diagnosed with the disorder, a parent will recognize that he or she had many of the same symptoms, and for the first time, will begin to understand some of the traits that have troubled them for years(4). All aspects of an individual's life must be considered in the diagnosis and treatment of ADHD(3).

Today's FDA approval was based on clinical trial data in adults ages 18 to 65. In these studies, use of CONCERTA(R) was shown to significantly improve ADHD symptoms such as attention, impulsivity and hyperactivity compared to placebo, and the medication was shown to be generally well tolerated.

About CONCERTA(R)

CONCERTA(R) is approved for the treatment of attention deficit hyperactivity disorder (ADHD) as part of a total treatment program that may include counseling or other therapies.

IMPORTANT SAFETY INFORMATION

Talk to your healthcare professional for a proper diagnosis and treatment of ADHD. Only a healthcare professional can decide whether medication is right for you or your child.

CONCERTA(R) should not be taken by patients who have: allergies to methylph
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & DevelopmentL.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
3. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
4. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
5. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
6. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
7. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
8. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
9. Medicare Approves in Home Sleep Apnea Testing
10. 3SBio Inc. Approves Share Repurchase Program
11. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... zFlo Motion , a US leader in biomechanics software ... a new partner. STT-Systems has developed an impressive ... with offerings in the optical-motion capture, 3D scanning, and industrial ... unit), iSen, is opening eyes around the world. With no ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Diagenode, ... such as the Bioruptor® and complete solutions for ... for chromatin immunoprecipitation, alleviating the need for manual ... controls needed for ChIP of histones or transcription ...
(Date:1/22/2015)...   GenoSpace , a precision medicine software company that has ... use of genomic, imaging and other biomedical data in research ... Munson , CEO of Aspera, an IBM Company, to its ... http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased to welcome ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... YORK, May 2 Pulmo BioTech Inc. (OTC,Bulletin Board: PLMO) ... Financial Officer., Pulmo BioTech Chief Executive Officer Garry McCann ... join the company and that Rajiv,s,experience and financial acumen would ... completion of its Phase I Human Trials and then into ...
... -- Quarterly Revenues Increase 62% to $11.7 million, ... million with EPS of $0.11, NEW YORK ... Pharma Holdings, Inc. ("China Pharma") (OTC Bulletin Board: ... products in China, today announced its financial results,for ...
... 7, 2008 at 10:00 AM EDT, CEDAR KNOLLS, ... ) will host a conference call discussing,its financial results ... May 7, 2008 at 10:00 AM EDT., A ... through the,company,s website at: http://www.emisphere.com . The live ...
Cached Biology Technology:Pulmo BioTech Announces Appointment of Chief Financial Officer 2Pulmo BioTech Announces Appointment of Chief Financial Officer 3China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 2China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 3China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 4China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 5China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 6China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 7China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 8China Pharma Holdings, Inc. Announces First Quarter 2008 Financial Results 9Emisphere Technologies, Inc. Announces Conference Call for First Quarter 2008 Financial Results 2
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   LaunchKey ... built for the post-password and Internet of Things era, ... seed funding. The venture round was led by Metamorphic ... Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in the ... One major trend emerging in this market is ... is important to upgrade biometric solutions to the latest ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... AGAWAM, Mass., May 13 Microtest Laboratories ... is adding dissolution testing to its current suite of ... services."The addition of dissolution testing ... said Steven Richter, Ph.D., President and Scientific Founder of Microtest ...
... May 20 Validus Technologies Corporation and HierStar ... formed a strategic manufacturing, marketing and distribution alliance ... Time Password (OTP) authentication products to combat cybercrime ... increasing data breaches, which have created a global ...
... scientists have identified two new genes and two new enzymes ... the plants were making monoterpenes, compounds that help give tomato ... the face of accepted thought. Such research could help ... Based on years of research, scientists thought that plants always ...
Cached Biology News:Microtest Labs Adds Dissolution Testing to its Suite of Analytical and Stability Testing Services 2Microtest Labs Adds Dissolution Testing to its Suite of Analytical and Stability Testing Services 3Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products 2Validus and HierStar Form Strategic Alliance to Offer the First Complete Range of Authentication Products 3MSU discoveries upend traditional thinking about how plants make certain compounds 2
...
... Purification with an Affinity Chitin-binding Tag) utilizes ... splicing elements (termed inteins) to purify recombinant ... (Figures 1 and 2). This system distinguishes ... its ability to separate a recombinant protein ...
... Note: The kit contains all the reagents ... of NADPH-cytochrome c reductase activity in cell ... [endoplastic reticulum (ER)]. It has been tested ... as liver, kidney, brain, spleen, and heart ...
... CHEMICON's Skeletal Myogenesis Kit provides the ... myoblasts into mature skeletal myotubes. By ... is a valuable tool in studies ... in developing strategies for muscle cell ...
Biology Products: